Antifungal prophylaxis and treatment in patients with hematological malignancies.
Invasive fungal infection (IFI) is a serious and common complication in hematological patients. The risk is highest among acute leukemia patients undergoing induction chemotherapy and patients undergoing allogeneic hematopoietic stem-cell transplantation. Owing to the difficulty in diagnosing IFIs and the fatality rate associated with delayed treatment, antifungal prophylaxis and empirical antifungal therapy are standard management approaches. Novel agents, such as posaconazole and echinocandins, broaden our armamentarium against IFIs and improve patients' outcomes.
Hwang
Yu Yan
YY
Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong. ghwang@graduate.hku.hk
Liang
Raymond
R
D000935:Antifungal Agents / Q000627:therapeutic use*; D019337:Hematologic Neoplasms / Q000150:complications*; D006801:Humans; D009181:Mycoses / Q000517:prevention & control*; D009894:Opportunistic Infections / Q000188:drug therapy
D000935:Antifungal Agents